HL23

• Catalog Number: orb1944267
• Category: Small Molecules
• Description: HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, modulating potassium channel activity and inducing TXNIP-dependent potassium deficiency. Additionally, HL23 impedes HCC progression and spread, demonstrating greater potency when combined with Sorafenib than the Sorafenib and Vorinostat duo [1].
• CAS Number: 1448355-15-4
• Purity: 98.00%
• MW: 712.83
• SMILES: O(C(=O)C1=CC=CC=C1)C2=C3C=4[C@](CC=5C=C(C(OC)=CC5)OC=6C=CC(C[C@]7(C8=CC(O3)=C(OC)C=C8CCN7C)[H])=CC6)(N(C)CCC4C=C2OC)[H]
• Formula: C₄₄H₄₄N₂O₇
• Biological Activity: HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, which in turn modulates potassium channel activity and induces TXNIP-dependent potassium deficiency. Additionally, HL23 impedes the advancement and spread of HCC and demonstrates a synergistic effect when combined with Sorafenib, exhibiting greater potency than the duo of Sorafenib and Vorinostat [1].
• Storage: -20°C
• Note: For research use only
• Expiration Date: 12 months from date of receipt.